Study Design and Baseline Characteristics of the CARDINAL Trial: A Phase 3 Study of Bardoxolone Methyl in Patients with Alport Syndrome

INTRODUCTION: Alport syndrome is a rare genetic disorder that affects as many as 60,000 persons in the USA and a total of 103,000 persons (<5 per 10,000) in the European Union [1, 2]. It is the second most common inherited cause of kidney failure and is characterized by progressive loss of kidney...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Am J Nephrol
Hlavní autoři: Chertow, Glenn M., Appel, Gerald B., Andreoli, Sharon, Bangalore, Sripal, Block, Geoffrey A., Chapman, Arlene B., Chin, Melanie P., Gibson, Keisha L., Goldsberry, Angie, Iijima, Kazumoto, Inker, Lesley A., Knebelmann, Bertrand, Mariani, Laura H., Meyer, Colin J., Nozu, Kandai, O'Grady, Megan, Silva, Arnold L., Stenvinkel, Peter, Torra, Roser, Warady, Bradley A., Pergola, Pablo E.
Médium: Artigo
Jazyk:Inglês
Vydáno: S. Karger AG 2021
Témata:
Patient-Oriented, Translational Research: Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8220919/
https://ncbi.nlm.nih.gov/pubmed/33789284
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000513777
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky